BRISTOL MYERS SQUIBB CO (BMY)
A+
Pipeline Grade
Financial Position (from SEC Filings)
$9,583.0M
Cash & Equivalents
$1,104.0M
Quarterly Burn Rate
$117,460M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (51 Assets)
| Drug | Phase | Indications |
|---|---|---|
|
AZTREONAM
AZACTAM IN PLASTIC CONTAINER |
APPROVED | — |
|
ENASIDENIB MESYLATE
IDHIFA |
APPROVED | — |
|
ENTECAVIR
BARACLUDE |
APPROVED | — |
|
NIVOLUMAB, RELATLIMAB-RMBW
OPDUALAG |
APPROVED | — |
|
APIXABAN
ELIQUIS |
APPROVED | — |
|
ABATACEPT
ORENCIA |
APPROVED | — |
|
DASATINIB
SPRYCEL |
APPROVED | — |
|
IPILIMUMAB
YERVOY |
APPROVED | — |
|
NIVOLUMAB
OPDIVO |
APPROVED | — |
|
ELOTUZUMAB
EMPLICITI |
APPROVED | — |
|
BELATACEPT
NULOJIX |
APPROVED | — |
|
AMINOSALICYLIC ACID RESIN COMPLEX
REZIPAS |
NDA | — |
|
ISONIAZID
NYDRAZID |
NDA | — |
|
DIDANOSINE
VIDEX |
NDA | — |
|
BUSPIRONE HYDROCHLORIDE
BUSPAR |
NDA | — |
|
METHOTREXATE SODIUM
MEXATE-AQ PRESERVED |
NDA | — |
|
FLUOXYMESTERONE
ORA-TESTRYL |
NDA | — |
|
GLIPIZIDE, METFORMIN HYDROCHLORIDE
METAGLIP |
NDA | — |
|
TRIFLUPROMAZINE HYDROCHLORIDE
VESPRIN |
NDA | — |
|
PRAVASTATIN SODIUM
PRAVACHOL |
NDA | — |
|
FOSINOPRIL SODIUM, HYDROCHLOROTHIAZIDE
MONOPRIL-HCT |
NDA | — |
|
AMPICILLIN/AMPICILLIN TRIHYDRATE
PRINCIPEN |
NDA | — |
|
ERYTHROMYCIN STEARATE
ETHRIL 500 |
NDA | — |
|
TRISULFAPYRIMIDINES (SULFADIAZINE, SULFAMERAZINE, SULFAMETHAZINE)
TERFONYL |
NDA | — |
|
VITAMIN A PALMITATE
VITAMIN A |
NDA | — |
|
ESTROGENS, ESTERIFIED
AMNESTROGEN |
NDA | — |
|
ETOPOSIDE PHOSPHATE
ETOPOPHOS PRESERVATIVE FREE |
NDA | — |
|
VINCRISTINE SULFATE
VINCREX |
NDA | — |
|
BLEOMYCIN SULFATE
BLENOXANE |
NDA | — |
|
TECHNETIUM TC-99M GLUCEPTATE KIT
GLUCOSCAN |
NDA | — |
|
CEPHRADINE
VELOSEF |
NDA | — |
|
RESERPINE
RAU-SED |
NDA | — |
|
ERGOLOID MESYLATES
DEAPRIL-ST |
NDA | — |
|
PROMETHAZINE HYDROCHLORIDE
REMSED |
NDA | — |
|
AMPHOTERICIN B
FUNGIZONE |
NDA | — |
|
WARFARIN SODIUM
COUMADIN |
NDA | — |
|
TESTOLACTONE
TESLAC |
NDA | — |
|
TUBOCURARINE CHLORIDE
TUBOCURARINE CHLORIDE |
NDA | — |
|
DIETHYLSTILBESTROL
STILBESTROL |
NDA | — |
|
FOSINOPRIL SODIUM
MONOPRIL |
NDA | — |
|
ACETAMINOPHEN, OXYCODONE HYDROCHLORIDE
OXYCODONE 5/APAP 500 |
NDA | — |
|
HYDROXYPROGESTERONE CAPROATE
DELALUTIN |
NDA | — |
|
PENICILLIN G SODIUM
PENICILLIN G SODIUM |
NDA | — |
|
EFAVIRENZ
SUSTIVA |
NDA | — |
|
ASPIRIN, PRAVASTATIN SODIUM
PRAVIGARD PAC (COPACKAGED) |
NDA | — |
|
HALCINONIDE
HALOG |
NDA | — |
|
MEGESTROL ACETATE
MEGACE |
NDA | — |
|
FLUPHENAZINE DECANOATE
PROLIXIN DECANOATE |
NDA | — |
|
AMITRIPTYLINE HYDROCHLORIDE
AMITID |
NDA | Advanced Cancer, Advanced Malignancies, Advanced or Metastatic (Medically or Surgically Unresectable) Clear-cell Renal Cell Carcinoma, Advanced or Metastatic Renal Cell Carcinoma, Advanced Renal Cell Carcinoma, Attention Deficit Hyperactivity Disorder, Brain Cancer, Brain Neoplasms, Broad Solid Tumor, Cancer, Carcinoma, Carcinoma, Non-Small-Cell Lung, Clear-cell Metastatic Renal Cell Carcinoma, Colorectal Cancer, Esophageal Adenocarcinoma, Esophageal Cancer, Gastric Cancer, Gastroesophageal-junction Cancer, HCC, Head & Neck Cancer, Head and Neck Cancer, Hepatitis B, Hepatocellular Carcinoma, HIV Infections, Hodgkin's Disease, Juvenile Idiopathic Arthritis, Liver Cancer, Lung Cancer, Lymphoma, Malignant Tumors, Melanoma, Mesothelioma, Metastatic Castration-resistant Prostrate Cancer, Metastatic Colorectal Cancer, Metastatic Melanoma, Metastatic Renal Cell Carcinoma, Muscle-Invasive Bladder Cancer, Muscle-invasive Urothelial Carcinoma, Non-small Cell Lung Cancer, Non-Small-Cell Lung Carcinoma, Non-small-cell-lu |
|
BUTORPHANOL TARTRATE
STADOL |
NDA | — |
|
STAVUDINE
ZERIT XR |
NDA | — |
Upcoming Catalysts
No upcoming catalysts detected for this company.
Active Clinical Trials (1)
| NCT # | Title | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT07169708 | A Retrospective Observational Study of Nivolumab in Combination With Chemotherapy as Neoadjuvant Therapy for Resectable ... | OTHER | Recruiting | 100 |
Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.